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V. Prulière-Escabasse 3 , G. Vuagniaux 1 , C. Clerici 2 , A. Coste 3 , C. Planès 2 . 1 Debiopharm, Lausanne, Switzerland; 2 INSERM773 CRB3, Paris 7, France; 3 INSERM841, Créteil, France EPI-hNE4, a specific inhibitor of human neutrophil elastase (hNE), has been proposed for treatment of cystic fibrosis (CF) lung disease because it may reduce hNE-induced lung tissue damage. Interestingly, it has been reported that the Epithelial Na+ Channel (ENaC), which is responsible for Na+ hyperabsorption in CF airways, could be activated by trypsin-like serine proteases such as Channel-Activating Proteases (CAP) expressed by airway epithelial cells or hNE released by neutrophils. EPI-hNE4 could then be useful in the treatment of CF lung disease by inhibiting hNE-induced increase in ENaC activity, in addition to its anti-elastolytic activity. We evaluated by short-circuit current (Isc) measurements the effects of hNE and EPI-hNE4 on ENaC activity in primary cultures of human nasal epithelial cells (HNEC) from control (9) and CF (2) patients. hNE or EPI-hNE4 treatment did not modify Isc in either normal or CF HNEC. However, hNE increased amiloridesensitive Isc in normal or CF HNEC pretreated with aprotinin, an inhibitor of CAP activity, and this effect was completely abolished in the presence of EPI-hNE4. These results indicate that hNE can activate in vitro ENaC and Na+ absorption in CF and normal HNEC, but that this effect is only seen after blockade of endogenous CAP activity. Thus, the pathophysiological importance of hNE-induced activation of ENaC in CF airways in vivo most likely depends on the level of CAP expression and activity in airway epithelial cells. Finally, the potent inhibitory effect of EPI-hNE4 on hNE-mediated ENaC activation observed in our experiments suggests that EPI-hNE4 could be of interest to reduce ENaC hyperactivity in CF airways in association with an inhibitor of CAP activity. CF patients are exposed to a lifelong and large burden of antibiotics. The goal of this project was to analyse the characteristics of allergic (immunopathologic) and non-immunopathologic (toxic) reactions in CF. We analysed all adverse drug reactions to antibiotics, which were noted routinely on a side-effect-sheet in the patients charts, during 2002 to 2004 in 379 CF patients attending the unit. In addition, we sent a questionnaire to all patients and compared the results with those from the charts. 251 questionnaires were returned and could be utilized, yielding a response rate of 66%. Of the 251 patients with questionnaires and chart records available, 80 experienced 187 reactions, of which 63 were immunopathologic, the others were classified as toxic. To specify the immunopathologic reactions further, these were divided into definitive (reproducible on exposition; n = 16), very likely (no reexposition tried, but no other explanation for the symptoms observed, n = 41). Of the immunopathologic reactions 47 (75.6%) were limited to the skin, and 4 (6.3%) to the skin and the respiratory tract. Shock (n = 2) or fever were noted only with iv treatment. A reduced frequency of immunopathologic reactions during iv treatment with cephalosporins was noted in patients with continuous oral cephalosporins (intake over 50%/year) treatment, in contrast to sporadic treatment (less than 50%/year). It is important to identify immunopathologic reactions. This helps to maintain the repertoire of drugs available for a specific patient. Intermittent intake of cephalosporins was associated with more reported allergic reactions to ivcephalosporins than continuous treatment. Not only basic CFTR mutation, but also other factors are involved in large phenotypic variance in CF, especially in respiratory tract. Due to the role of mannosebinding lectin (MBL) in innate immune mechanism and reported association of MBL deficiency and susceptibility to various infections, we therefore investigated possible influence of MBL2 gene polymorphism on the phenotype of CF. Material and Methods: MBL2 gene promotor polymorphisms (at position −550 and −221) and mutations in the gene coding region (codons 52, 54, 57 within exon 1) were determined in 168 CF patients and 255 controls by multiplex PCR. MBL concentrations in serum (168 CF patients, 80 controls) and BAL supernatants (45 CF, 100 controls) were measured using ELISA. Corresponding MBL2 gene polymorphisms and concentrations were compared with lung function (FEV 1 ) and clinical status. Results: MBL2 gene polymorphisms strongly correlate with MBL serum and BAL concentrations. CF patients bearing MBL genotype associated with low MBL levels tended to have lower MBL serum levels compared with healthy controls with the same MBL genotype. These patients with genetically determined low MBL production presented with worse lung function, however, they were able to produce high levels of this lectin during acute exacerbation of an infection. MBL concentrations in BAL were lower than in serum (p < 0.01). Conclusions: Independently of the MBL genetic pattern, CF patients differ widely in mainly respiratory phenotype. Severe lung function deterioration is caused by concurrence between CFTR mutation, many other modifier genes (not just one) and enviromental influences. Supported by: IGA NR8458−5 and VZ 64203.
